Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
24 participants
OBSERVATIONAL
2014-04-30
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We are testing healthy adults in this study, and eventually would like to apply to persons who have neurologic disorders such as stroke or dystonia. By applying a magnetic field to the outside of the head, electrical currents are produced within the brain that can stimulate brain tissue. Using TMS, the brain can be studied to gain a greater understanding of the mechanisms associated with cortical excitability in healthy and patient populations. There is limited knowledge of what influence genetic biomarkers such as BDNF have on cortical excitability changes within the cortex following learning. Studies have indicated that people without this certain gene are less likely to show changes in brain excitability during TMS and during motor learning than people with this gene
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Motor Neuron Tests
NCT01517087
In-depth Investigation of Brain Network Interactions
NCT04748146
Explore the Nature Factors Relevant to Learning-Pioneering Natural Factors That Influences Science Learning II
NCT00713570
The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans
NCT01260740
Investigating the Role of Brain-derived Neurotrophic Factor (BDNF) Between Pain and Other Neuronal Disease
NCT03606915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion/ Exclusion Criteria: Inclusion criteria include ages between 18-45 years and no past history of psychiatric or neurologic disease. Exclusion criteria include subjects with any neuromuscular disorder that impairs upper extremity motion or seizure history. Subjects cannot be pregnant nor have indwelling metal or medical devices that are incompatible with TMS testing.
With the subject seated in a supportive chair, the subject's skin will be cleaned surrounding the first doral interoseus belly and dorsum of the hand. Next small surface electromyographic (EMG) electrodes will be attached at the muscle belly and tendon. A ground electrode will be placed on the dorsum of the hand or wrist.
Next, the threshold for TMS activation of the target muscle will be determined. To find the optimal position for activating the first dorsal interosseous muscle, we will use a 70-mm figure-eight TMS coil connected to a Magstim rapid magnetic stimulator. The coil will be handheld on the scalp over the approximate area of the primary motor cortex (M1) in the contralateral hemisphere to the recording electrode, and moved systematically to find the optimal position. Single-pulse magnetic stimuli will be delivered manually at approximately 0.1 Hz starting at an intensity of 50% of the stimulator maximum. This level will be adjusted systematically until the resting motor threshold is found, defined as the minimum intensity required to elicit a motor evoked potential (MEP) \>50 µV peak-to-peak in at least 5 of 10 trials with the target muscle at rest. Various cortical excitability measures will be collected lasting approximately 20 minutes.
Finger tracking/training will be provided for 30 minutes under the supervision of the PI or Co-I. Subjects will wear a finger electrogoniometer at the index finger metacarpophalangeal (MP) joint. Subjects will use flexion/extension movements of the respective joint to track waveforms on a computer screen. The training would consist of 30 blocks of tracking trials. Each block will consist of 3 trials. The protocol parameters for different blocks will differ in waveform, amplitude, frequency, trial duration, and joint position. For example, a square wave would involve a different movement pattern execution as opposed to a triangular wave. The waveforms may also differ on the forearm position to create "stimulus-response compatible" or "stimulus-response incompatible" conditions. For example, a stimulus-response incompatible joint position would involve extending and flexing the joint (finger MP or elbow) in the horizontal plane to produce cursor movements in the vertical plane. All these factors challenge the individual's capabilities to problem solve to achieve optimum learning.
Following training and accuracy testing, cortical excitability measures will be collected again lasting approximately 20 minutes. Lastly, a saliva sample will be collected for genetic screening for brain derived neurotrophic factor (BDNF) polymorphism. We will collect approximately 2 ml (less than one-half teaspoon) of saliva by asking the subject to spit into a tube. It may take up to 30 minutes to provide a saliva sample, however, most people typically require less time (approximately 5 minutes).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no past history of psychiatric or neurologic disease.
Exclusion Criteria
* Pregnancy
* Indwelling metal or medical device that are incompatible with TMS testing.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teresa J Kimberley, PhD, PT
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401M46962
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.